Company AngioGenex, Inc.

AngioGenex, Inc. is a biopharmaceutical company, which is engaged in discovering and development of Id protein inhibitors to address unmet medical needs in oncology and ophthalmology. The Company and its collaborators, including Robert Benezra, Ph.D. and The Robert Benezra Lab at Sloan Kettering Institute, have assembled key platform enabling technologies and tools that allow for the identification of specific and potent small molecule binders of Id. Its Anti-Id platform gave rise to AGX-A, an investigational small molecule designed to selectively bind to Id proteins, thereby targeting them for degradation and reducing resulting tumor growth and neovascularization. The Company’s lead development candidate is AGX-A, a small molecule being investigated for the treatment of cholangiocarcinoma and age-related macular degeneration (AMD).